Stagezero advertises Aristotle cancer test > SZLS.WT at 0.08 STAGEZERO LIFE SCIENCES INTRODUCES ARISTOTLE, THE FIRST MULTI-CANCER TEST FROM A SINGLE SAMPLE OF BLOOD
On Thursday, April 1, Stagezero Life Sciences Ltd. announced it was partnering with Health Clinics and Care Oncology to launch the early cancer diagnostic program AVRT centred around Aristotle, Stagezero's multicancer test.
The Aristotle female panel includes nine tests for cancer: ovarian, breast, cervical, endometrial, colorectal, bladder, stomach, liver and nasopharyngeal. The Aristotle male panel includes six tests for cancer: prostate, colorectal, bladder, stomach, liver and nasopharyngeal. Using an approach called immunoediting, Aristotle interrogates the mRNA from whole blood to detect gene expression profiles indicative of specific cancers. It is the first multicancer test to come to market with the ability to test for multiple, discrete cancers from a single sample of blood.
AVRT, under the direction of Dr. Padman Vamadevan at Care Oncology, targets early disease, with a specific focus on cancer, utilizing consultations with oncologists who individualize diagnosis and any subsequent treatment. Aristotle will be priced at $1,500 (U.S.) and will initially be offered to Care Oncology's current U.S. patients (over 3,000) as well as immediate family concerned about their own risk for cancer. AVRT begins immediately.
"COVID-19 has significantly altered the current health care landscape but has positioned us well: it has propelled telehealth to the dominant means by which to work with patients, it is generating good revenue for us -- Q3 and Q4 2020 and continuing into Q1 2021, and has allowed us to build out our organization and finance it to market Aristotle," said James Howard-Tripp, chairman and chief executive officer of Stagezero Life Sciences. "The team at Health Clinics/Care Oncology will significantly enhance our clinical and scientific capability, adding depth and affiliations with key cancer centres as well as expanding the executive and the board. The partnership also gives us the necessary infrastructure to correctly cater to employers, where we go next."
Further updates on the AVRT program and the acquisition will come in the weeks ahead.
About Stagezero Life Sciences Ltd.
Stagezero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The company operates a College of American Pathologists-accredited and Clinical Laboratory Improvement Amendments of 1988-certified high complexity reference laboratory based in Richmond, Va. A specialist in PCR testing for the early identification of cancer through blood, the company is uniquely positioned to provide both COVID-19 PCR testing (swab and saliva) and blood test analysis (antibody testing). The company's full-service telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. As it provides COVID-19 testing during this pandemic, the company continues making progress with its mission to eradicate late-stage cancers through early detection. The company's next-generation test, Aristotle, is a multicancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.